Late donor cardiectomy after paediatric heterotopic cardiac transplantation

The Lancet

Volumn 374, Issue 9687, 2009, Pages 387-392

  Tsang, V ^a   Yacoub, M ^b   Sridharan, S ^a   Burch, M ^a   Radley Smith, R ^a   Khaghani, A ^b   Savoldo, B ^c   Amrolia, PJ ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ELSILIMOMAB; MONOCLONAL ANTIBODY; PREDNISOLONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CARDIOPULMONARY BYPASS; CASE REPORT; CHILD; CLINICAL FEATURE; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DRUG DOSE REDUCTION; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART OUTPUT; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; ORGAN DONOR; ORTHOTOPIC TRANSPLANTATION; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RELAPSE; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INFECTION;

EID: 67651252909     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61201-0     Document Type: Article

References (34)

1. Lipshultz S.E., Sleeper L.A., Towbin J.A., et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348 (2003) 1647-1655
2. Nugent A.W., Daubeney P.E., Chondros P., et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 348 (2003) 1639-1646
3. Strauss A., and Lock J.E. Pediatric cardiomyopathy-a long way to go. N Engl J Med 348 (2003) 1703-1705
4. Boucek M.M., Mashburn C., Dunn S.M., et al. Pediatric heart transplantation after declaration of cardiocirculatory death. N Engl J Med 359 (2008) 709-714
5. Curfman G.D., Morrissey S., and Drazen J.M. Cardiac transplantation in infants. N Engl J Med 359 (2008) 749-750
6. Khaghani A., Santini F., Dyke C.M., et al. Heterotopic cardiac transplantation in infants and children. J Thorac Cardiovasc Surg 113 (1997) 1042-1048
7. Yacoub M. Heart transplantation: the end of the beginning. Am J Transplant 8 (2008) 1767-1768
8. Webber S.A., Naftel D.C., Fricker F.J., et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 367 (2006) 233-239
9. Smith R.R., Wray J., Khaghani A., and Yacoub M. Ten year survival after paediatric heart transplantation: a single centre experience. Eur J Cardiothorac Surg 27 (2005) 790-794
10. Morris-Thurgood J., Cowell R., Paul V., et al. Hemodynamic and metabolic effects of paced linkage following heterotopic cardiac transplantation. Circulation 90 (1994) 2342-2347
11. Savoldo B., Goss J.A., Hammer M.M., et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108 (2006) 2942-2949
12. Yacoub M.H. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J 22 (2001) 534-540
13. Frazier O.H., and Myers T.J. Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg 68 (1999) 734-741
14. Dandel M., Weng Y., Siniawski H., et al. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation 112 (2005) I37-I45
15. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355 (2006) 1873-1884
16. Hayashi R.J., Kraus M.D., Patel A.L., et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 23 (2001) 14-18
17. Gao S.Z., Chaparro S.V., Perlroth M., et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 22 (2003) 505-514
18. Rickinson A.B., Lee S.P., and Steven N.M. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 8 (1996) 492-497
19. Pinkerton C.R., Hann I., Weston C.L., et al. Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol 118 (2002) 456-461
20. Maloney D.G. Mechanism of action of rituximab. Anticancer Drugs 12 suppl 2 (2001) S1-S4
21. Milpied N., Vasseur B., Parquet N., et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11 suppl 1 (2000) 113-116
22. Choquet S., Leblond V., Herbrecht R., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 107 (2006) 3053-3057
23. Haddad E., Paczesny S., Leblond V., et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97 (2001) 1590-1597
24. Gross T.G., Bucuvalas J.C., Park J.R., et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 23 (2005) 6481-6488
25. Swinnen L.J., Mullen G.M., Carr T.J., Costanzo M.R., and Fisher R.I. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86 (1995) 3333-3340
26. Suryanarayan K., Natkunam Y., Berry G., et al. Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation. J Pediatr Hematol Oncol 23 (2001) 452-455
27. Dotti G., Fiocchi R., Motta T., et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 74 (2002) 1095-1102
28. Buell J.F., Gross T.G., Hanaway M.J., et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 37 (2005) 956-957
29. Rooney C.M., Smith C.A., Ng C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 (1998) 1549-1555
30. Gustafsson A., Levitsky V., Zou J.Z., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95 (2000) 807-814
31. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110 (2007) 1123-1131
32. Comoli P., Labirio M., Basso S., et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99 (2002) 2592-2598
33. Sawada S., Suzuki G., Kawase Y., and Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 139 (1987) 1797-1803
34. Savoldo B., Goss J., Liu Z., et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 72 (2001) 1078-1086